{
  "id": 1767779665752,
  "title": "Retinopathy of Prematurity (ROP) & Pediatric Retinal Disorders: A Comprehensive Clinical Guide",
  "summary": "An exhaustive clinical resource detailing the history, risk factors, ICROP classification, UK screening and treatment guidelines, and related pediatric retinal pathologies. This poster covers the full spectrum of ROP management from initial screening to long-term follow-up and differential diagnosis.",
  "date": "2026-01-07T09:54:25.752Z",
  "data": {
    "title": "Retinopathy of Prematurity (ROP) & Pediatric Retinal Disorders: A Comprehensive Clinical Guide",
    "summary": "An exhaustive clinical resource detailing the history, risk factors, ICROP classification, UK screening and treatment guidelines, and related pediatric retinal pathologies. This poster covers the full spectrum of ROP management from initial screening to long-term follow-up and differential diagnosis.",
    "summary_illustration": "<svg viewBox='0 0 200 200' xmlns='http://www.w3.org/2000/svg'><circle cx='100' cy='100' r='80' fill='none' stroke='hsl(215, 90%, 45%)' stroke-width='2'/><circle cx='100' cy='100' r='30' fill='none' stroke='hsl(215, 90%, 45%)' stroke-width='1' stroke-dasharray='4'/><circle cx='100' cy='100' r='55' fill='none' stroke='hsl(215, 90%, 45%)' stroke-width='1' stroke-dasharray='4'/><path d='M100 70 A30 30 0 0 1 130 100' fill='none' stroke='red' stroke-width='3'/><text x='100' y='105' font-family='Arial' font-size='10' text-anchor='middle' fill='hsl(215, 90%, 45%)'>ROP</text></svg>",
    "sections": [
      {
        "title": "History and the Oxygen Compromise",
        "icon": "history",
        "type": "plain_text",
        "layout": "half_width",
        "color_theme": "blue",
        "content": "ROP was first reported in 1942. By the 1950s, it was the leading cause of childhood blindness. At this point, tight oxygen control was introduced, with a dramatic fall in ROP, but a significant rise in neonatal death and neurological disability. Oxygen delivery is now a compromise between these factors."
      },
      {
        "title": "Primary Risk Factors",
        "icon": "warning",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "red",
        "content": [
          "Low gestational age (<32wk).",
          "Low birthweight (<1,501g).",
          "High or variable oxygen tension."
        ]
      },
      {
        "title": "ICROP Classification: The 5 Stages of ROP",
        "icon": "layers",
        "type": "process",
        "layout": "full_width",
        "color_theme": "purple",
        "content": [
          "Stage 1: Demarcation line—flat, white line separating vascular from avascular zones.",
          "Stage 2: Ridge—line becomes elevated and thickened, may become pinkish with neovascular tufts (‘popcorn’) posterior to ridge.",
          "Stage 3: Ridge with extraretinal fibrovascular proliferation—vascular tissue grows from posterior margin on to retina or into the vitreous.",
          "Stage 4: Subtotal retinal detachment—extrafoveal (4A) or foveal (4B).",
          "Stage 5: Total retinal detachment."
        ]
      },
      {
        "title": "Vascular Activity: Plus and Pre-plus Disease",
        "icon": "Emergency_Home",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "red",
        "content": [
          "Plus disease: significant venous dilatation and arteriolar tortuosity (compared with a standard photograph) of the posterior retinal vessels in two or more quadrants.",
          "Pre-plus disease: more venous dilatation and arteriolar tortuosity than normal, but insufficient to be defined as plus disease."
        ]
      },
      {
        "title": "Location and Extent",
        "icon": "map",
        "type": "mindmap",
        "layout": "half_width",
        "color_theme": "green",
        "content": {
          "center": "Anatomy",
          "branches": [
            "Zone I: Circle centered on the disc, radius twice the distance from disc center to fovea.",
            "Zone II: Ring centered on the disc, from zone 1 to ora nasally and equator temporally.",
            "Zone III: Remaining temporal crescent.",
            "Extent: Measured in clock-hours."
          ]
        }
      },
      {
        "title": "Threshold and Prethreshold Disease (ETROP)",
        "icon": "rule",
        "type": "table",
        "layout": "full_width",
        "color_theme": "yellow",
        "content": {
          "headers": [
            "Category",
            "Criteria / Definition"
          ],
          "rows": [
            [
              "Threshold Disease",
              "Originally an estimate of equal progression/regression; defined as Stage 3 ROP with plus disease in zones I or II and 5 continuous or 8 non-continuous clock-hours."
            ],
            [
              "Prethreshold Type 1 (Treat)",
              "Zone I, any stage ROP with plus disease; Zone I, stage 3 ROP +/- plus disease; Zone II, stage 2 or 3 ROP with plus disease."
            ],
            [
              "Prethreshold Type 2 (Monitor)",
              "Zone I, stage 1 or 2 ROP without plus disease; Zone II, stage 3 ROP without plus disease."
            ]
          ]
        }
      },
      {
        "title": "UK ROP Screening Guidelines (Table 18.34)",
        "icon": "visibility",
        "type": "table",
        "layout": "full_width",
        "color_theme": "blue",
        "content": {
          "headers": [
            "Category",
            "Criteria and Timing"
          ],
          "rows": [
            [
              "Must be Screened",
              "All babies born at <31wk gestational age (up to 30wk and 6d) OR <1,251g birthweight."
            ],
            [
              "Should be Screened",
              "All babies born at <32wk gestational age (up to 31wk and 6d) OR <1,501g birthweight (good practice)."
            ],
            [
              "1st Exam (<27wk GA)",
              "First exam to be at 30–31wk post-menstrual age."
            ],
            [
              "1st Exam (27-32wk GA)",
              "First exam to be at 4–5wk postnatal age."
            ],
            [
              "1st Exam (>32wk but <1501g)",
              "First exam to be at 4–5wk postnatal age (Must occur prior to discharge)."
            ],
            [
              "Weekly Screening",
              "If vessels end in zone I or posterior zone II, OR any plus/pre-plus disease, OR any stage 3 disease (any zone)."
            ],
            [
              "Fortnightly Screening",
              "All other circumstances where termination criteria not reached."
            ]
          ]
        }
      },
      {
        "title": "Screening Technique & Termination",
        "icon": "medical_services",
        "type": "key_point",
        "layout": "full_width",
        "color_theme": "green",
        "content": [
          "Technique: Indirect ophthalmoscopy (28D lens). Dilate 1h prior (cyclopentolate 0.5% + phenylephrine 2.5%; 2–3 doses). Consider sterilized lid speculum and scleral indentation.",
          "Clinical Caution: Beware of the positions of all tubes/lines that may be vulnerable to a clumsy ophthalmologist.",
          "Termination (No ROP): Vascularization extended into zone III (usually after 36 completed weeks post-menstrual age).",
          "Termination (With ROP): Two successive exams showing: Lack of increase in severity; Partial resolution; Color change in ridge (salmon-pink to white); Vessels crossing demarcation line; Replacement of active ROP by scar tissue.",
          "Note: Any stage 3 disease may require long-term follow-up."
        ]
      },
      {
        "title": "UK Treatment Guidelines (Table 18.35)",
        "icon": "healing",
        "type": "table",
        "layout": "full_width",
        "color_theme": "purple",
        "content": {
          "headers": [
            "Aspect",
            "Management Guideline"
          ],
          "rows": [
            [
              "Treat (Mandatory)",
              "Zone I, any ROP with plus; Zone I, stage 3 without plus; Zone II, stage 3 with plus."
            ],
            [
              "Consider Treating",
              "Zone II, stage 2 with plus disease."
            ],
            [
              "Timing: Aggressive ROP",
              "Treat as soon as possible (<48h)."
            ],
            [
              "Timing: Other ROP",
              "Treat within 48–72h."
            ],
            [
              "Technique",
              "Transpupillary diode laser; near-confluent (0.5–1 burn-width) to entire avascular retina. Cryotherapy/argon laser if diode is unavailable."
            ],
            [
              "Post-treatment FU",
              "1st exam 5–7d post-treatment. Then at least weekly looking for activity/regression."
            ],
            [
              "Retreatment",
              "If failure to regress 10–14d post-initial treatment."
            ]
          ]
        }
      },
      {
        "title": "Treatment Modalities & Outcomes",
        "icon": "biotech",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "blue",
        "content": [
          "Cryotherapy: Used for >30y; largely replaced by laser.",
          "Laser Photocoagulation: Diode laser is more portable, better tolerated, and more effective for posterior disease.",
          "Intravitreal Anti-VEGF: Used for posterior ROP or high ventilation risk. Requires long-term follow-up for neurodevelopmental effects.",
          "Vitreoretinal Surgery: Aims to repair RD (Stages 4A, 4B, 5). Results are generally disappointing."
        ]
      },
      {
        "title": "Long-Term Complications",
        "icon": "monitoring",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "yellow",
        "content": [
          "Myopia (often severe).",
          "Retinal folds and dragging of the macula.",
          "Amblyopia and Strabismus.",
          "Retinal detachment at the border of treated/untreated retina.",
          "Follow-up: Spontaneous Stage 3 or treated ROP babies reviewed until at least 5y of age."
        ]
      },
      {
        "title": "Differential: ROP-like Syndromes",
        "icon": "group_work",
        "type": "table",
        "layout": "full_width",
        "color_theme": "purple",
        "content": {
          "headers": [
            "Condition",
            "Genetics & Features"
          ],
          "rows": [
            [
              "FEVR (Familial Exudative Vitreoretinopathy)",
              "AD (Chr 11q) or XR (NDP gene). Abrupt vessel cessation at equator. Ischaemia leads to proliferation, folds, macular ectopia, RD, and subretinal exudation (Coats-like)."
            ],
            [
              "Incontinentia Pigmenti (Bloch–Sulzberger)",
              "XD (usually lethal in males). 80% NEMO gene deletion (Xq28). ROP-like vessels, gliosis, TRD. Systemic: teeth anomalies, cutaneous pigment whorls, CNS anomalies."
            ],
            [
              "Retinal Dysplasia",
              "Abnormal optic cup development. Clinical: Folds, RD, haems, retrolental grey mass, phthisis bulbi. Syndromes: Patau, Edwards, Norrie (deafness, low IQ), Walker–Warburg."
            ]
          ]
        }
      },
      {
        "title": "Other Retinochoroidal Disorders in Children",
        "icon": "list",
        "type": "plain_text",
        "layout": "full_width",
        "color_theme": "blue",
        "content": "Discussed elsewhere in clinical literature: RP (Retinitis pigmentosa), CSNB (Congenital stationary night blindness), macular dystrophies, chorioretinal dystrophies, hereditary vitreoretinal degenerations, albinism, and Coats’ disease/Leber’s miliary aneurysms."
      },
      {
        "title": "References & Literature Cited",
        "icon": "menu_book",
        "type": "plain_text",
        "layout": "full_width",
        "color_theme": "green",
        "content": "11. International Committee for the Classification of Retinopathy of Prematurity. The International Classification of Retinopathy of Prematurity revisited. Arch Ophthalmol. 2005;123:991–9. | 12. Good WV. Early Treatment for Retinopathy of Prematurity Cooperative Group. Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial. Trans Am Ophthalmol Soc. 2004;102:233–48. | Data sourced from RCPCh, RCOphth, BAPN, BLISS. Guideline for the screening and treatment of retinopathy of prematurity 2008."
      }
    ]
  },
  "chapterId": "pediatric",
  "seqId": 61
}